Literature DB >> 20460518

Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells.

Dimple Chakravarty1, Sujit S Nair, Bindu Santhamma, Binoj C Nair, Long Wang, Abhik Bandyopadhyay, Joseph K Agyin, Darrell Brann, Lu-Zhe Sun, I-Tien Yeh, Francis Y Lee, Rajeshwar Rao Tekmal, Rakesh Kumar, Ratna K Vadlamudi.   

Abstract

The molecular basis of breast cancer progression to metastasis and the role of estrogen receptor (ER) signaling in this process remain poorly understood. Emerging evidence suggests that ER participates in extranuclear signaling in addition to genomic functions. Recent studies identified proline-, glutamic acid-, and leucine-rich protein-1 (PELP1) as one of the components of ER signalosome in the cytoplasm. PELP1 expression is deregulated in metastatic breast tumors. We examined the mechanism and significance of ER-PELP1-mediated extranuclear signals in the cytoskeletal remodeling and metastasis. Using estrogen dendrimer conjugate (EDC) that uniquely activate ER extranuclear signaling and by using model cells that stably express PELP1 short hairpin RNA (shRNA), we show that PELP1 is required for optimal activation of ER extranuclear actions. Using a yeast two-hybrid screen, we identified integrin-linked kinase 1 (ILK1) as a novel PELP1-binding protein. Activation of extranuclear signaling by EDC uniquely enhanced E2-mediated ruffles and filopodia-like structures. Using dominant-negative and dominant-active reagents, we found that estrogen-mediated extranuclear signaling promotes cytoskeleton reorganization through the ER-Src-PELP1-phosphoinositide 3-kinase-ILK1 pathway. Using in vitro Boyden chamber assays and in vivo xenograft assays, we found that ER extranuclear actions contribute to cell migration. Collectively, our results suggest that ER extranuclear actions play a role in cell motility/metastasis, establishing for the first time that endogenous PELP1 serves as a critical component of ER extranuclear actions leading to cell motility/invasion and that the ER-Src-PELP1-ILK1 pathway represents a novel therapeutic target for preventing the emergence of ER-positive metastasis. (c)2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20460518      PMCID: PMC2889925          DOI: 10.1158/0008-5472.CAN-09-3834

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

Review 1.  Treatment for advanced tumors: SRC reclaims center stage.

Authors:  Justin M Summy; Gary E Gallick
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

2.  Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action.

Authors:  William R Harrington; Sung Hoon Kim; Cory C Funk; Zeynep Madak-Erdogan; Rachel Schiff; John A Katzenellenbogen; Benita S Katzenellenbogen
Journal:  Mol Endocrinol       Date:  2005-11-23

3.  Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression*.

Authors:  W Q Zheng; J Lu; J M Zheng; F X Hu; C R Ni
Journal:  Steroids       Date:  2001-12       Impact factor: 2.668

Review 4.  Signaling regulation of genomic and nongenomic functions of estrogen receptors.

Authors:  Filippo Acconcia; Rakesh Kumar
Journal:  Cancer Lett       Date:  2005-08-03       Impact factor: 8.679

5.  Estrogen induces lung metastasis through a host compartment-specific response.

Authors:  Carole L Banka; Caren V Lund; Mai T N Nguyen; Andrew J Pakchoian; Barbara M Mueller; Brian P Eliceiri
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

Review 6.  Tumour-cell invasion and migration: diversity and escape mechanisms.

Authors:  Peter Friedl; Katarina Wolf
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

Review 7.  SRC in human carcinogenesis.

Authors:  Salvatore V Russello; Scott K Shore
Journal:  Front Biosci       Date:  2004-01-01

8.  Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc.

Authors:  Frank Barletta; Chi-Wai Wong; Chris McNally; Barry S Komm; Benita Katzenellenbogen; Boris J Cheskis
Journal:  Mol Endocrinol       Date:  2004-02-12

9.  p41-Arc subunit of human Arp2/3 complex is a p21-activated kinase-1-interacting substrate.

Authors:  Ratna K Vadlamudi; Feng Li; Christopher J Barnes; Rozita Bagheri-Yarmand; Rakesh Kumar
Journal:  EMBO Rep       Date:  2004-01-23       Impact factor: 8.807

10.  The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype.

Authors:  Hany Onsy Habashy; Desmond G Powe; Emad A Rakha; Graham Ball; R Douglas Macmillan; Andrew R Green; Ian O Ellis
Journal:  Breast Cancer Res Treat       Date:  2009-06-03       Impact factor: 4.872

View more
  50 in total

1.  Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer.

Authors:  Vei Mah; Diana Marquez; Mohammad Alavi; Erin L Maresh; Li Zhang; Nam Yoon; Steve Horvath; Lora Bagryanova; Michael C Fishbein; David Chia; Richard Pietras; Lee Goodglick
Journal:  Lung Cancer       Date:  2011-04-20       Impact factor: 5.705

Review 2.  Extranuclear signaling by estrogen: role in breast cancer progression and metastasis.

Authors:  V Cortez; M Mann; D W Brann; R K Vadlamudi
Journal:  Minerva Ginecol       Date:  2010-12

3.  Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.

Authors:  Vijay K Gonugunta; Gangadhara R Sareddy; Samaya Rajeshwari Krishnan; Valerie Cortez; Sudipa Saha Roy; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Mol Cancer Ther       Date:  2014-03-31       Impact factor: 6.261

4.  PELP1 signaling contributes to medulloblastoma progression by regulating the NF-κB pathway.

Authors:  Yiliao Luo; Mengxing Li; Uday P Pratap; Suryavathi Viswanadhapalli; Junhao Liu; Prabhakar P Venkata; Kristin A Altwegg; Bridgitte E Palacios; Xiaonan Li; Yihong Chen; Manjeet K Rao; Andrew J Brenner; Gangadhara R Sareddy; Ratna K Vadlamudi
Journal:  Mol Carcinog       Date:  2019-12-24       Impact factor: 4.784

5.  Luminal breast cancer metastasis is dependent on estrogen signaling.

Authors:  Vidya Ganapathy; Whitney Banach-Petrosky; Wen Xie; Aparna Kareddula; Hilde Nienhuis; Gregory Miles; Michael Reiss
Journal:  Clin Exp Metastasis       Date:  2012-03-17       Impact factor: 5.150

6.  Nuclear receptor liver receptor homologue 1 (LRH-1) regulates pancreatic cancer cell growth and proliferation.

Authors:  Cindy Benod; Maia V Vinogradova; Natalia Jouravel; Grace E Kim; Robert J Fletterick; Elena P Sablin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

7.  Rapid estrogen signaling negatively regulates PTEN activity through phosphorylation in endometrial cancer cells.

Authors:  Melanie M Scully; Leslie K Palacios-Helgeson; Lah S Wah; Twila A Jackson
Journal:  Horm Cancer       Date:  2014-05-21       Impact factor: 3.869

8.  Cytoplasmic ERα and NFκB Promote Cell Survival in Mouse Mammary Cancer Cell Lines.

Authors:  Emily Smart; Luis H Alejo; Jonna Frasor
Journal:  Horm Cancer       Date:  2020-02-01       Impact factor: 3.869

Review 9.  Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer.

Authors:  Viroj Boonyaratanakornkit; Nalo Hamilton; Diana C Márquez-Garbán; Prangwan Pateetin; Eileen M McGowan; Richard J Pietras
Journal:  Mol Cell Endocrinol       Date:  2017-11-14       Impact factor: 4.102

10.  PELP1 oncogenic functions involve CARM1 regulation.

Authors:  Monica Mann; Valerie Cortez; Ratna Vadlamudi
Journal:  Carcinogenesis       Date:  2013-03-13       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.